is a member of the American Headache Society, The International
Headache Society and The National Headache Foundation. Dr. Goldstein
is a Board Certified Neurologist, a Fellow of the American Academy of
Neurology, and has special qualification for the treatment of headache
from the National Headache Foundation. He has received many industry
awards, published articles in industry journals and served on advisory
boards related to the development of a wide range of headache
-- Alan J. Tuchman, M.D., Clinical Professor of Neurology and
Pharmacology at New York Medical College, Principal of a
neuroscience-focused consulting firm and a board-certified neurologist
Dr. Tuchman will present information about glutamate receptors in the
spinal cord as a target for muscle spasticity. He has served as Vice
Chairman of the Department of Neurology at New York Medical College as
well as Vice Dean of Clinical Affairs, which involved the development
and management of clinical care and medical education policy for 29
affiliated hospitals. In addition, he was President of the Epilepsy
Society of Southern New York. Dr. Tuchman is a frequent speaker about
neuroscience topics at academic meetings.
"There's a growing body of scientific and clinical evidence that supports the further development of drugs that block the glutamate cascade," said Dr. Kurtz. "As the American Headache Society prepares to kick off its 50th Annual Scientific Meeting, we want to provide patients as well as the medical community with industry experts' perspectives as to what is clearly a promising approach for the treatment of migraine and other conditions."
TorreyPines Therapeutics' lead compound, tezampanel is the first
AMPA/kainate-type glutamate receptor antagonist
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved